This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into EYEN's ophthalmology pipeline for in-office pupil dilation & presbyopia before October 28th PDUFA for MydCombi

Ticker(s): EYEN, ABBV, OCUP

Who's the expert?

Institution: Keystone Retina Associates

  • Clinician, researcher, author and lecturer specializing in complex vitreo retinal surgery and medical retinal conditions.
  • Manages 600 patients with wet-AMD and 250 patients with presbyopia.
  • Clinical Trial Investigator on studies for macular degeneration, diabetic macular edema, retinal vein occlusion, and more.

Interview Questions
Q1.

Roughly how many patients with presbyopia do you currently manage?

Added By: c_admin
Q2.

If approved where do you see MydCombi being utilized in your practice compared to existing agents?

Added By: c_admin
Q3.

What are your thoughts on the VISION-1 Phase 3 Clinical Study of MicroLine? How does this compare to the Phase 3 GEMINI 1 study of AGN-190584?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.